Drug Trial News

RSS

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

While therapeutic advances have improved survival of patients with follicular lymphoma (FL), it remains an incurable disease with inevitable relapse. This underscores the need for therapies and strategies to extend the duration of remission without significantly increasing toxicity and while maintaining quality of life.

15 Sep 2011

Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes

Ultra-long-acting insulin degludec, an investigational basal insulin being developed by Novo Nordisk, showed significant blood sugar reductions in patients with type 2 diabetes.

From Novo Nordisk 15 Sep 2011

Patients with hepatitis C may benefit from 24 week telaprevir-based regimen

University of Cincinnati research published in the Sept. 14, 2011, advance online edition of the New England Journal of Medicine shows that patients with hepatitis C who took a combination medication-a telaprevir-based regimen that is commonly used to treat the illness-for 24 weeks were cured.

15 Sep 2011

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

Alexion Pharmaceuticals, Inc. today announced that the Company's study of eculizumab in a small group of 14 patients with severe and refractory generalized myasthenia gravis, an ultra-rare and debilitating form of generalized myasthenia gravis (gMG), showed a strong disease improvement signal.

15 Sep 2011

First effective blood-stage vaccine against malaria

Scientists have identified the first effective blood-stage malaria vaccine, according to a New England Journal of Medicine study from University of Maryland School of Medicine researchers, in collaboration with the University of Bamako in Mali, West Africa, and other partners.

15 Sep 2011

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

Vertex Pharmaceuticals Incorporated today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK (telaprevir) tablets in people with genotype 1 chronic hepatitis C who were new to treatment.

15 Sep 2011

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

SARcode Bioscience, Inc., a privately-held biopharmaceutical company, announced today that the initial patient has been enrolled in the company's pivotal Phase 3 clinical study (OPUS-1) of SAR 1118 ophthalmic solution.

15 Sep 2011

Scientist granted over $138,000 to explore Vitamin C therapy in sepsis

Sepsis kills more people than breast, colorectal, pancreatic, and prostate cancers combined. Outside of coronary care units, it is the leading cause of mortality in intensive care units. Every year 18 million people worldwide develop this potentially fatal disease. Thanks to a generous grant of $138,238.65 from the Jesse and Julie Rasch Foundation, Lawson Health Research Institute's Dr. Michael Sharpe is exploring a new sepsis therapy using Vitamin C.

15 Sep 2011

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.

15 Sep 2011

Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1 clinical study of VT-1161, an oral, potent and selective antifungal agent. VT-1161 is a novel small molecule discovered by Viamet Pharmaceuticals using its proprietary Metallophile Technology.

14 Sep 2011

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Aeterna Zentaris Inc. earlier today, presented positive final Phase 2 efficacy and safety data for its targeted cytotoxic luteinizing hormone releasing hormone (LHRH) analog, AEZS-108, in advanced endometrial cancer.

14 Sep 2011

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.

14 Sep 2011

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Pfizer Oncology announced today that data evaluating crizotinib in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC), as well as data from Pfizer's renal cell carcinoma (RCC) portfolio on axitinib, an investigational compound, and SUTENT(sunitinib malate) will be presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden, September 23 - 27, 2011.

14 Sep 2011

Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma

Nanobiotix, a company developing novel cancer nanotherapeutics, announced today that its lead compound NBTXR3 has received the formal authorization from the French Medicine Agency, AFSSAPS, to start the first clinical trial.

14 Sep 2011

Lexicon's LX4211 clinical data presented at EASD annual meeting

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company is presenting clinical data this week at the European Association for the Study of Diabetes (EASD) annual meeting in Lisbon, Portugal.

14 Sep 2011

VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting

VIVUS, Inc. today presented positive results from the avanafil phase 3 study in diabetics. In the REVIVE-Diabetes study (TA-302), male diabetics receiving avanafil had significant improvement in erectile function.

14 Sep 2011

ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE

ViroPharma Incorporated and Halozyme Therapeutics announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze in combination with Halozyme's Enhanze technology, a proprietary drug delivery platform using Halozyme's recombinant human hyaluronidase enzyme, in subjects with hereditary angioedema.

14 Sep 2011

Drug Trial News

NCCN 6th annual congress discusses role of maintenance therapies in follicular lymphoma

Novo Nordisk's insulin degludec reduces blood sugar in patients with type 2 diabetes

Patients with hepatitis C may benefit from 24 week telaprevir-based regimen

Encouraging results from Alexion's eculizumab Phase 2 study on generalized myasthenia gravis

First effective blood-stage vaccine against malaria

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

SARcode Bioscience initiates enrollment in SAR 1118 Phase 3 study for dry eye disease

Scientist granted over $138,000 to explore Vitamin C therapy in sepsis

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

Viamet commences VT-1161 Phase 1 clinical study to treat fungal infections

Positive data from Aeterna Zentaris' AEZS-108 Phase 2 study on advanced endometrial cancer

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

New data from Pfizer's investigational oncology compounds to be presented at EMCC 2011

Nanobiotix starts clinical trial of new cancer treatment for soft tissue sarcoma

Lexicon's LX4211 clinical data presented at EASD annual meeting

VIVUS presents positive results from avanafil phase 3 study in diabetics at 47th EASD meeting

ViroPharma initiates Cinryze Phase 2 subcutaneous trial in patients with HAE

Acceleron commences ACE-536 Phase 1 clinical trial in anemia

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

Researchers use MRI and PET/CT to assess safety, efficacy of heart drug dalcetrapib

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News